Published source snapshot
I3C Indole 3-Carbinol 200
LifeLink · US label facts
Label IDlbl_dsld_11766_639451712e47e28f
Serving size1 Capsule(s)
Serving formCapsule(s)
Retrieved
Scope: source-market status describes the source record, not live availability. Quantities below are label facts and deterministic arithmetic, not a product recommendation.
Original facts and normalized results
| Ingredient | Original label quantity | Requested normalization | Measurement object |
|---|---|---|---|
| Indole-3-Carbinol (I3C) DSLD row path: root.0; DSLD ingredientId: 47064 | 200 mg | 200 mg / as_labeled | Indole-3-Carbinol |
| Maltodextrin Listed as an other ingredient; no amount is supplied. DSLD ingredientId: 282516. | Not stated | missing_quantity | Maltodextrin |
| Silicon Listed as an other ingredient; no amount is supplied. DSLD ingredientId: 280319. | Not stated | missing_quantity | Silicon Dioxide |
| Magnesium stearate Listed as an other ingredient; no amount is supplied. DSLD ingredientId: 34937. | Not stated | missing_quantity | Magnesium Stearate |
Label statements
These are explicitly classified as label claims. They are not converted into platform-endorsed scientific conclusions.
- label_claim Suggested/Recommended/Usage/Directions: Suggested Use: One capsule daily, or as directed by your qualified healthcare provider.
- label_claim General Statements: All Other Content: Indole-3-carbinol (I3C) inhibits hormonal pathways involved in the development of cancers such as breast, cervical, colon, ovarian, and prostate cancers, and laryngeal papillomas. I3C is used as a preventative - it cannot inhibit tumors once they have started. When a precancerous condition is detected, an I3C supplement may prevent progression to cancer or even bring about a remission. A complete remission of Cervical Dysplasia is obtained in about 50% of cases when I3C is taken orally at 200-400 mg/day for 12 weeks.
Ingredient references
Reference pages provide verified source mappings. Unless a real review record exists, they remain reference-only with no medical summary or evidence grade.
Source and version
- Original record
- NIH ODS DSLD label 11766
- Local snapshot
- snap_dsld_11766_639451712e47e28fdda2150a
- Content hash
639451712e47e28fdda2150a2a19494f3e8be69be062bc3c1a787c7f677eb101- Source version
- Not stated
Limitations
- This record reports label facts from a US-market source snapshot, not current inventory or product safety.
- Label quantity comparisons do not establish absorption, efficacy, safety, or clinical equivalence.